Clinical trials: Advanced Solid Malignancy
Ovarian Cancer, TNBC, SCLC, Other Solid Tumours
Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours
This is an open-label, multi-centre, Phase Ib study of AZD1775 designed to assess the safety, tolerability, pharmacokinetics, and anti-tumour activity of AZD1775 monotherapy in patients with advanced solid tumours.
- Trial name
- NCT02482311
- Testing
- AZD 1775
- Where
- 16 sites in United States, Canada
- Volunteers
- 92 people
- Sponsor
- AstraZeneca
Advanced Liver Cancer
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid Tumor
This is an open-label phase 1 study with an escalation part and an expansion part.
- Trial name
- NCT04906434
- Testing
- ABSK-011
- Where
- 32 sites in United States, China and 1 more
- Volunteers
- 200 people
- Sponsor
- Abbisko Therapeutics Co, Ltd
Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies
The purpose of the study is to find out if an investigational drug called PRGN-3007 UltraCAR-T cells (PRGN-3007 T cells) can help people with ROR1-positive hematologic chronic lymphocytic leukemia (CLL), mantle cell lymphoma…
- Conditions
- Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma
- Trial name
- NCT05694364
- Testing
- Fludarabine, Cyclophosphamide, PRGN-3007
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Advanced/Metastatic Solid Tumors
ADG116 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
This is a Phase 1b, open-label, dose escalation study to evaluate the safety, tolerability, PK, and immunogenicity of an ADG116-pembrolizumab combination regimen in patients with advanced/metastatic solid tumors.
- Trial name
- NCT05277402
- Testing
- ADG116
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Adagene Inc
Advanced Solid Tumors
NK521 in the Treatment of Malignant Ascites Associated With Advanced Solid Tumors
Study Population: Adult subjects aged 18-75 years with relapsed/refractory advanced solid tumors (including liver, gastric, colorectal, ovarian cancer, etc.) and malignant ascites confirmed by cytology, who have failed at least 2…
- Trial name
- NCT07561437
- Testing
- NK521 Cell Injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Base Therapeutics (Shanghai) Co., Ltd.
Advanced Solid Tumors (Such as Gastric Cancer), Advanced Solid Tumors (Such as Adenocarcinoma at the Gastroesophageal Junction)
A IIT Study of 177Lu-DOTA-SNA040
This clinical trial is a single-center, open-label, non-randomized, first-in-human (FIH), dose-escalation study evaluating the safety, tolerability, and preliminary efficacy of 177Lu-DOTA-SNA040 in patients with advanced…
- Conditions
- Advanced Solid Tumors (Such as Gastric Cancer), Advanced Solid Tumors (Such as Adenocarcinoma at the Gastroesophageal Junction), Advanced Solid Tumors (Such as Pancreatic Cancer), Advanced Solid Tumors (Such as Cholangiocarcinoma)
- Trial name
- NCT07595237
- Testing
- 177Lu-DOTA-SNA040
- Where
- China
- Volunteers
- 12 people
- Sponsor
- SmartNuclide Biopharma
MUC1-expressing Advanced, Relapsed and/or Refractory Solid Tumors, Non-Small Cell Lung Cancer
Evaluation of XYA02 in Patients With Advanced Solid Tumors
This study will evaluate the safety, tolerability, and efficacy of XYA02 in participants with advanced solid tumors.
- Conditions
- MUC1-expressing Advanced, Relapsed and/or Refractory Solid Tumors, Non-Small Cell Lung Cancer, Ovarian Cancer, GEJ Adenocarcinoma
- Trial name
- NCT07670312
- Testing
- XYA02
- Where
- 5 sites in Australia
- Volunteers
- 190 people
- Sponsor
- XYone Therapeutics, Inc
Tumor, Solid
BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab
A Phase 1 Open-label Dose Escalation Study of BDB001 in Combination with Atezolizumab in Subjects with Advanced Solid Tumors
- Trial name
- EIK1001 (NCT04196530)
- Testing
- BDB001 (EIK1001), Atezolizumab
- Where
- 5 sites in United States
- Volunteers
- 40 people
- Sponsor
- Eikon Therapeutics
Breast Cancer, Non Small Cell Lung Cancer
Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression
This study evaluated ADCT-502 in participants with Advanced Solid Tumors with HER2 Expression. Participants participated in a dose-escalation phase (Part 1) and were due to participate in the dose expansion phase (Part 2).
- Conditions
- Breast Cancer, Non Small Cell Lung Cancer, GastroEsophageal Cancer, Bladder Cancer
- Trial name
- NCT03125200
- Testing
- ADCT-502
- Where
- 5 sites in United States, Belgium
- Volunteers
- 21 people
- Sponsor
- ADC Therapeutics S.A.
Advanced Malignant Solid Tumor
Clinical Study of VG161 in Subjects With Advanced Malignant Solid Tumors
VG161 is a recombinant human-IL12/15/PDL1B oncolytic HSV-1 Injectable. This Phase I study will be conducted in HSV-seropositive subjects with advanced malignant solid tumors that are refractory to conventional therapies.
- Trial name
- NCT04758897
- Testing
- Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))
- Where
- 2 sites in China
- Volunteers
- 18 people
- Sponsor
- CNBG-Virogin Biotech (Shanghai) Ltd.
Triple Negative Breast Cancer Metastatic, Melanoma Metastatic
A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors.
This study focuses on the treatment of liver metastases from three common cancers: colorectal cancer, triple-negative breast cancer and melanoma.
- Conditions
- Triple Negative Breast Cancer Metastatic, Melanoma Metastatic, Colorectal Cancer Metastatic
- Trial name
- NCT06889610
- Testing
- MTT(Multimodal Tumor Thermal Therapy System)- Colorectal Cancer, MTT(Multimodal Tumor Thermal Therapy System)- Triple-Negative Breast Cancer, MTT(Multimodal Tumor Thermal Therapy System)- Melanoma
- Where
- China
- Volunteers
- 95 people
- Sponsor
- Fudan University
Triple Negative Locally Advanced Non-resectable Breast Cancer, HR+, HER2-, Advanced Breast Cancer
A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors
This is a Phase 1b/2, Open-label Study to Investigate the Safety and Efficacy of Invikafusp alfa (STAR0602), a Selective T Cell Receptor (TCR)-targeting, Bifunctional Antibody-fusion Molecule, in Combination with Sacituzumab…
- Trial name
- START-002 (NCT06827613)
- Testing
- STAR0602, Sacituzumab Govitecan (SG)
- Where
- 8 sites in United States, Canada
- Volunteers
- 50 people
- Sponsor
- Marengo Therapeutics, Inc.
Solid Tumor
MAX-10181 in Patients With Advanced Solid Tumor
This is a multi-center, open-label, single-arm, dose-escalation Phase I study to evaluate the safety and tolerability of MAX-10181 in patients with advanced solid tumor.
- Trial name
- PD-L1 (NCT05196360)
- Testing
- MAX-10181
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Maxinovel Pty., Ltd.
Malignancies
Study of PWT33597 Mesylate in Subjects With Advanced Malignancies
This is a Phase 1 study evaluating the safety, pharmacokinetics, pharmacodynamics, and clinical effects of orally administered PWT33597 mesylate in subjects with advanced malignancies.
- Trial name
- NCT01407380
- Testing
- PWT33597 mesylate
- Where
- 4 sites in United States
- Volunteers
- 22 people
- Sponsor
- Pathway Therapeutics, Inc.
Non-small Cell Lung Cancer, Colorectal Cancer
A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors
This is a Phase 1, first-in-human, open-label dose-escalation study to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) and assess the DLT of JAB-3312.
- Conditions
- Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Carcinoma, Esophageal Squamous Cell Carcinoma
- Trial name
- NCT04045496
- Testing
- JAB-3312
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
Advanced Relapsed Tumors, Refractory Solid Tumors
A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10
This is an open-label Phase 1a/b dose-escalation study to assess the safety, tolerability, and PK of OMP-131R10 as a single agent for advanced solid tumors and in subjects with metastatic colorectal cancer.
- Trial name
- NCT02482441
- Testing
- OMP-131R10, FOLFIRI
- Where
- 7 sites in United States
- Volunteers
- 50 people
- Sponsor
- OncoMed Pharmaceuticals, Inc.
Recurrent Prostate Cancer, Stage IV Prostate Cancer
Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors
This phase I trial is studying the side effects and best dose of combination chemotherapy in treating patients with metastatic or unresectable solid tumors.
- Conditions
- Recurrent Prostate Cancer, Stage IV Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00058253
- Testing
- tanespimycin, docetaxel
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumor
A Clinical Study Evaluating the Safety and Efficacy of Anti-HER2-CAR-T Cells Injection in Patients With Solid Tumors
This is a single-center, open-label clinical study of anti-HER2-CAR-T cells for HER2+ patients with locally advanced and/or metastatic solid tumors.
- Trial name
- NCT06101082
- Testing
- Intravenous infusion anti-HER2-CAR-T cell
- Where
- China
- Volunteers
- 9 people
- Sponsor
- China Medical University, China
Mesothelin-positive Advanced Malignant Solid Tumors
Anti-Mesothelin CAR-T Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid Tumors
This is a single-arm, open-label, exploratory clinical study to evaluate the safety, tolerability and preliminary efficacy of Anti-Mesothelin CAR-T cell injection in patients with Mesothelin-positive advanced malignant solid…
- Trial name
- NCT07010523
- Testing
- Anti-mesothelin CAR-T cells, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 24 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Advanced Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification
This phase II trial studies how well AZD1775 works in treating patients with solid tumors with CCNE1 amplification that have spread to other places in the body (advanced) and do not respond to treatment (refractory).
- Trial name
- NCT03253679
- Testing
- Adavosertib
- Where
- 9 sites in United States
- Volunteers
- 31 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.